慢性阻塞性肺疾病诊断、管理和预防全球倡议:2020年GOLD科学委员会关于COVID-19与慢性阻塞性肺疾病的报告
GOLD科学委员会采用既定文献综述方法,概述了COVID-19大流行期间COPD患者的管理。目前尚不清楚COPD患者感染SARS-CoV-2的风险是否增加。在COVID-19社区流行率高期间,肺功能检查仅应在对COPD诊断和/或评估肺功能状态以进行介入操作或手术必需时使用。COPD患者应遵循基本感染控制措施(社交距离、洗手、戴口罩或面部遮挡),并保持适当疫苗接种(尤其是每年流感疫苗接种)。吸入激素、长效支气管舒张剂、罗氟司特或长期大环内酯类药物应按稳定期COPD管理指征继续使用;COPD急性加重时全身激素和抗生素按常规指征使用。
要点
- 在COVID-19社区流行率高期间,肺功能检查仅应在对COPD诊断和/或评估肺功能状态以进行介入操作或手术必需时使用。
- COPD患者应遵循基本感染控制措施,包括社交距离、洗手和戴口罩或面部遮挡。
- COPD患者应保持适当疫苗接种,尤其是每年流感疫苗接种。
- 吸入激素、长效支气管舒张剂、罗氟司特或长期大环内酯类药物应按稳定期COPD管理指征继续使用。
- COPD急性加重时全身激素和抗生素按常规指征使用;怀疑COVID-19时应考虑检测SARS-CoV-2。
适用人群与场景
- COPD患者,涵盖稳定期管理与急性加重期管理。
- 发生中度至重度COVID-19(包括住院和肺炎)的COPD患者。
- 发生无症状或轻度COVID-19的COPD患者。
- 发生中度或更差COVID-19的COPD患者。
诊断标准与关键阈值
- 目前尚不清楚COPD患者感染SARS-CoV-2的风险是否增加。
- 区分COVID-19感染症状与慢性基础症状或急性COPD加重症状可能具有挑战性;如怀疑COVID-19,应考虑检测SARS-CoV-2。
处置流程与药物剂量
- 在COVID-19社区流行率高期间,肺功能检查仅应在对COPD诊断和/或评估肺功能状态以进行介入操作或手术必需时使用。
- COPD患者应遵循基本感染控制措施,包括社交距离、洗手和戴口罩或面部遮挡。
- COPD患者应保持适当疫苗接种,尤其是每年流感疫苗接种。
- 吸入激素、长效支气管舒张剂、罗氟司特或长期大环内酯类药物应按稳定期COPD管理指征继续使用。
- COPD急性加重时全身激素和抗生素按常规指征使用。
- 发生中度至重度COVID-19(包括住院和肺炎)的患者应按不断演变的药物治疗方法适当治疗,包括瑞德西韦、地塞米松和抗凝治疗。
- COPD合并重度急性呼吸窘迫综合征患者的急性呼吸衰竭管理应包括适当氧疗、俯卧位通气、无创通气和保护性肺策略。
- 发生无症状或轻度COVID-19的患者应按常规COPD方案随访;发生中度或更差COVID-19的患者应比常规COPD患者更频繁和准确地监测,尤其注意氧疗需求。
研究设计与关键结果
- GOLD科学委员会采用既定文献综述方法,概述了COVID-19大流行期间COPD患者的管理。
- 目前尚不清楚COPD患者感染SARS-CoV-2的风险是否增加。
- 区分COVID-19感染症状与慢性基础症状或急性COPD加重症状可能具有挑战性。
证据类型、等级与局限
- 证据类型:指南/共识(GOLD科学委员会报告),采用既定文献综述方法。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在COVID-19社区流行率高期间,肺功能检查仅应在对COPD诊断和/或评估肺功能状态以进行介入操作或手术必需时使用。
- COPD患者应遵循基本感染控制措施,包括社交距离、洗手和戴口罩或面部遮挡。
- COPD患者应保持适当疫苗接种,尤其是每年流感疫苗接种。
- 吸入激素、长效支气管舒张剂、罗氟司特或长期大环内酯类药物应按稳定期COPD管理指征继续使用,不应因COVID-19大流行而常规停用。
- COPD急性加重时全身激素和抗生素按常规指征使用。
- 如怀疑COVID-19,应考虑检测SARS-CoV-2。
- 发生中度至重度COVID-19(包括住院和肺炎)的COPD患者应按不断演变的药物治疗方法适当治疗,包括瑞德西韦、地塞米松和抗凝治疗。
- COPD合并重度急性呼吸窘迫综合征患者的急性呼吸衰竭管理应包括适当氧疗、俯卧位通气、无创通气和保护性肺策略;发生中度或更差COVID-19的患者应比常规COPD患者更频繁和准确地监测,尤其注意氧疗需求。
指南或共识出处
- Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has raised many questions about the management of patients with chronic obstructive pulmonary disease (COPD) and whether modifications of their therapy are required. It has raised questions about recognizing and differentiating coronavirus disease (COVID-19) from COPD given the similarity of the symptoms. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee used established methods for literature review to present an overview of the management of patients with COPD during the COVID-19 pandemic. It is unclear whether patients with COPD are at increased risk of becoming infected with SARS-CoV-2. During periods of high community prevalence of COVID-19, spirometry should only be used when it is essential for COPD diagnosis and/or to assess lung function status for interventional procedures or surgery. Patients with COPD should follow basic infection control measures, including social distancing, hand washing, and wearing a mask or face covering. Patients should remain up to date with appropriate vaccinations, particularly annual influenza vaccination. Although data are limited, inhaled corticosteroids, long-acting bronchodilators, roflumilast, or chronic macrolides should continue to be used as indicated for stable COPD management. Systemic steroids and antibiotics should be used in COPD exacerbations according to the usual indications. Differentiating symptoms of COVID-19 infection from chronic underlying symptoms or those of an acute COPD exacerbation may be challenging. If there is suspicion for COVID-19, testing for SARS-CoV-2 should be considered. Patients who developed moderate-to-severe COVID-19, including hospitalization and pneumonia, should be treated with evolving pharmacotherapeutic approaches as appropriate, including remdesivir, dexamethasone, and anticoagulation. Managing acute respiratory failure should include appropriate oxygen supplementation, prone positioning, noninvasive ventilation, and protective lung strategy in patients with COPD and severe acute respiratory distress syndrome. Patients who developed asymptomatic or mild COVID-19 should be followed with the usual COPD protocols. Patients who developed moderate or worse COVID-19 should be monitored more frequently and accurately than the usual patients with COPD, with particular attention to the need for oxygen therapy.
参考来源
- Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021. PMID: 33146552. doi:10.1164/rccm.202009-3533SO
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。